Last reviewed · How we verify
Co-amoxiclav
Co-amoxiclav is a combination antibiotic that kills bacteria by inhibiting cell wall synthesis (amoxicillin) while protecting the amoxicillin from enzymatic degradation (clavulanic acid).
Co-amoxiclav is a combination antibiotic that kills bacteria by inhibiting cell wall synthesis (amoxicillin) while protecting the amoxicillin from enzymatic degradation (clavulanic acid). Used for Bacterial infections caused by beta-lactamase-producing organisms (respiratory tract infections, urinary tract infections, skin and soft tissue infections, otitis media), Mixed aerobic and anaerobic infections.
At a glance
| Generic name | Co-amoxiclav |
|---|---|
| Also known as | Augmentin Duo, Augmentin |
| Sponsor | Imperial College London |
| Drug class | Beta-lactam antibiotic with beta-lactamase inhibitor |
| Target | Bacterial penicillin-binding proteins (PBPs); bacterial beta-lactamases |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Amoxicillin is a beta-lactam antibiotic that binds to penicillin-binding proteins and inhibits bacterial cell wall cross-linking, leading to cell lysis. Clavulanic acid is a beta-lactamase inhibitor that irreversibly binds to bacterial beta-lactamases, preventing them from breaking down amoxicillin and extending its spectrum of activity against beta-lactamase-producing organisms.
Approved indications
- Bacterial infections caused by beta-lactamase-producing organisms (respiratory tract infections, urinary tract infections, skin and soft tissue infections, otitis media)
- Mixed aerobic and anaerobic infections
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Rash
- Abdominal pain
- Allergic reactions (including anaphylaxis)
Key clinical trials
- APLAUD Trial (Antibiotics vs PLacebo for Acute Uncomplicated Diverticulitis) (PHASE2)
- Fast Track Therapeutic Model in Acute Complicated Appendicitis in Pediatrics (PHASE4)
- Efficacy of an Empirical Treatment With Amoxicillin-clavulanate (AC) Compared to the Combination Amoxicillin-clavulanate and Ciprofloxacin (AC+C) in the Outpatient Care of Chemotherapy-induced Fever in Adult Haematology Patients. (PHASE3)
- Amoxicillin/Clavulanic Acid Susceptibility in Acute Community-acquired Pneumonia Requiring Intensive Care Management
- Comparative Efficacy of Antibiotics for Small Intestine Bacterial Overgrowth in Bangladeshi Children (PHASE2)
- Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Acute Sinusitis (PHASE4)
- Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP (PHASE4)
- A Platform Trial for Gram Negative Bloodstream Infections (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Co-amoxiclav CI brief — competitive landscape report
- Co-amoxiclav updates RSS · CI watch RSS
- Imperial College London portfolio CI